Cancer Lumps on Dogs: Benign vs. Malignant Differentials, FNA Cytology, Mast Cell Tumor Grading, Soft Tissue Sarcoma Margins, and Treatment Modalities

Key Takeaways

• Not all lumps on dogs are cancerous, and the majority of skin masses in dogs evaluated by veterinarians are benign. The most common benign skin and subcutaneous masses include lipomas (benign tumors of mature adipocytes, extremely common in middle-aged and older dogs – particularly Labrador Retrievers, Dobermans, and mixed breeds), sebaceous cysts (cystic accumulations of keratin and sebaceous secretions within hair follicles), histiocytomas (benign Langerhans cell tumors that spontaneously regress in 1-3 months, typically in dogs under 3 years), papillomas (viral warts caused by canine papillomavirus, especially in young dogs and immunosuppressed dogs), and perianal adenomas (benign apocrine gland tumors in intact male dogs). These benign entities are extremely common and account for the majority of skin lumps found on routine examination in otherwise healthy dogs.
• The single most important clinical principle in evaluating a dog’s lump is that physical examination characteristics – size, texture, mobility, borders, growth rate, and appearance – cannot reliably distinguish benign from malignant masses. A mast cell tumor (the most common malignant skin tumor in dogs) can appear identical on palpation to a lipoma: soft, well-defined, subcutaneous, slowly growing. Conversely, many benign masses present with alarming features such as rapid growth, irregular borders, or surface ulceration. The only reliable method for determining a mass’s nature is tissue sampling and cytological or histopathological examination. Veterinary oncologists and dermatologists consistently emphasize: “every lump deserves a diagnosis.” The appropriate response to a new lump is not observation until it “looks concerning” but sampling at the time of discovery.
• Fine needle aspirate (FNA) cytology is the first-line diagnostic tool for most accessible skin and subcutaneous lumps. FNA involves inserting a 22-25 gauge needle into the mass and collecting cells by aspiration or capillary action, then expressing the collected cells onto a glass slide for staining and microscopic examination. The procedure requires no sedation in most dogs, takes minutes, and provides immediate diagnostic information. FNA has high diagnostic accuracy for certain tumor types – mast cell tumors, lymphoma, and lipomas are often definitively diagnosed by cytology alone. It has lower accuracy for mesenchymal tumors (soft tissue sarcomas) where cell exfoliation is poor and the architecture of tissue invasion is necessary for grading. When FNA is non-diagnostic or inconclusive, excisional or incisional biopsy for histopathology is the next step. Histopathology provides both diagnosis and histological grade – the critical factor for prognosis and treatment planning in many tumors.
• Mast cell tumor (MCT) is the most common malignant skin tumor in dogs, accounting for approximately 16-21% of all canine skin tumors. It arises from mast cells in the dermis and subcutis and can occur anywhere on the body, with the trunk and limbs most commonly affected. MCT behavior ranges from locally invasive low-grade tumors with excellent prognosis following complete surgical excision to high-grade tumors with early metastasis and poor prognosis despite aggressive therapy. Histological grading (Patnaik 3-tier system or Kiupel 2-tier system) is the most important prognostic factor. Mast cells contain cytoplasmic granules with histamine, heparin, and other vasoactive amines – MCTs can cause paraneoplastic signs including gastric ulceration (from histamine-stimulated H2 receptors increasing gastric acid), local erythema and wheal formation (Darier’s sign) when manipulated, and rarely systemic anaphylaxis from massive degranulation. Dogs with known or suspected MCT should not have their tumor repeatedly manipulated before surgical removal.
• Soft tissue sarcoma (STS) is a broad category encompassing malignant tumors of mesenchymal origin arising in soft tissues (fibrosarcoma, peripheral nerve sheath tumor, hemangiopericytoma, liposarcoma, myxosarcoma, and others). STS tumors typically feel firm, locally invasive, poorly demarcated from surrounding tissue, and may appear deceptively “encapsulated” on palpation – but this apparent capsule is actually a pseudocapsule of compressed tumor cells, not true surgical margins. The critical clinical implication is that tumor finger-like projections extend well beyond the palpable margins, meaning that surgery that removes only the apparent mass without wide margins (typically 2-3 cm in all directions including deep margin) results in microscopic residual disease and local recurrence in the majority of cases. First surgery is the best opportunity for cure – STS in sites where wide margins are impossible at first surgery has a significantly worse prognosis than the same tumor grade removed with wide clear margins initially.